Mar. 18 at 7:12 PM
$AVXL "Summary of the Event Studies
"Based on the event studies on Biogen’s Aducanumab and Lilly’s Donanemab, the value of a drug candidate at or ready for Phase 3 trial would be worth
$20.2 billion to
$20.7 billion, and a Breakthrough Therapy Designation has a value of
$13.4 billion. An Alzheimer’s drug approved by the FDA carries a market value of
$43.4 billion."
This was back in 2021 pre recent inflation.
So what should blarcamesine be valued at, especially with it's ABCLEAR data?
https://ipwatchdog.com/2021/10/26/assessing-much-alzheimers-drug-worth/
